Fate Therapeutics Inc (FATE) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Fate Therapeutics Inc (FATE) has a cash flow conversion efficiency ratio of -0.104x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-24.37 Million) by net assets ($234.07 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See FATE net asset quality index to measure how much of total assets are equity-financed.
Fate Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2011–2024)
This chart illustrates how Fate Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Fate Therapeutics Inc (FATE) reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Fate Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Fate Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Decisive Dividend Corp
V:DE
|
0.050x |
|
VYTRUS BIOTECH EO -01
F:V5P
|
N/A |
|
Daedong Ind
KO:000490
|
0.039x |
|
Wah Hong Industrial
TWO:8240
|
0.029x |
|
Loandepot Inc
NYSE:LDI
|
0.100x |
|
C&C International Corp.
KQ:352480
|
0.045x |
|
GoldMoney Inc
TO:XAU
|
0.050x |
|
Lara Exploration Ltd.
V:LRA
|
-0.091x |
Annual Cash Flow Conversion Efficiency for Fate Therapeutics Inc (2011–2024)
The table below shows the annual cash flow conversion efficiency of Fate Therapeutics Inc from 2011 to 2024. For the full company profile with market capitalisation and key ratios, see Fate Therapeutics Inc (FATE) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $318.73 Million | $-122.87 Million | -0.386x | -7.39% |
| 2023-12-31 | $368.42 Million | $-132.26 Million | -0.359x | +30.00% |
| 2022-12-31 | $483.94 Million | $-248.21 Million | -0.513x | -113.77% |
| 2021-12-31 | $678.84 Million | $-162.87 Million | -0.240x | -135.13% |
| 2020-12-31 | $384.44 Million | $-39.23 Million | -0.102x | +69.97% |
| 2019-12-31 | $244.76 Million | $-83.17 Million | -0.340x | -41.09% |
| 2018-12-31 | $160.47 Million | $-38.65 Million | -0.241x | +49.62% |
| 2017-12-31 | $77.19 Million | $-36.91 Million | -0.478x | -17.28% |
| 2016-12-31 | $73.15 Million | $-29.82 Million | -0.408x | +15.71% |
| 2015-12-31 | $38.04 Million | $-18.40 Million | -0.484x | +38.86% |
| 2014-12-31 | $28.34 Million | $-22.42 Million | -0.791x | -161.66% |
| 2013-12-31 | $50.85 Million | $-15.37 Million | -0.302x | -220.32% |
| 2012-12-31 | $-52.83 Million | $-13.27 Million | 0.251x | +4.86% |
| 2011-12-31 | $-50.68 Million | $-12.14 Million | 0.240x | -- |
About Fate Therapeutics Inc
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma; FT836 whiuch is in preclinical stage for multiple tumor types; and FT522, to treat… Read more